Clinical Trial Update: A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of GLASSIA for acute graft-versus-host disease (GvHD) was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Glassia (alpha-1 proteinase inhibitor)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Graft Versus Host Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2019-04-24